Mutagenicity Studies on Nonspecific Immunostimulator BARODON®
Journal of Toxicology and Public Health Vol.19 No.2, 2003. 6
Min-Su Seo, Sung-Dae Cho, Nam-Shik Ahn, Ji-Won Jung, Se-Ran Yang, Joon-Suk Park, Ki-Su Park, In-Sun Hong, Eun-Hye Jo, Nguyen Ba Tiep, Yong-Soon Lee, Kyung-Sun Kang.
A nonspecific immunostimulator BARODON® was tested for mutagenicity using Ames Salmonella tester strains TA98, TA100, TA102, TA1535 and TA1537 with or without metabolic activation (S9 mix). None of the fresh species showed mutagenicity. In the reverse mutation test using Salmonella typhimurium TA98, TA100, TA102, TA1535 and TA1537 did not increase the number of revertants at all doses tested (5, 2.5 or 1.25 mg/ml). Chromosome aberration test was carried out in Chinese hamster lung (CHL) cell line. The cells were treated with BARODON® (1, 0.5 or 0.25 mg/ml), while positive control group was treated with Mitomycin C (0.1 mg/ml). The results show that there is no statistically significant difference between positive control and treatment groups. In mouse micronucleus test, there was significant increase in the ratio of micronucleated polychromatic erythrocyte (MNPCE) in the high dose group (10% BARODON®), while there is no significance between control and low (2.5% BARODON®) or middle (5% BARODON®) dose groups. Taken togather, this results suggest that below 5% BARODON® might not have mutagenic potential in vitro and vivo systems.
